Core Viewpoint - 华领医药-B (02552) has shown significant growth in its mid-term performance, indicating successful commercialization and operational efficiency improvements [1] Financial Performance - 华堂宁 sales reached 1.764 million boxes, a year-on-year increase of 108% [1] - Net sales amounted to 217.4 million yuan, reflecting a 112% year-on-year growth [1] - The company reported a one-time deferred income of 1.2435 billion yuan following the termination of the exclusive promotion agreement with Bayer [1] - The company achieved a profit of 1.1839 billion yuan in the first half of the year, marking its first profitable period [1] - Gross margin increased to 54.2%, up 7.7 percentage points from the same period last year [1] Operational Highlights - The company has significantly increased its sales through its own sales team since taking over the commercialization of 华堂宁 in January 2025 [1] - There has been a substantial increase in prescription volumes in secondary and tertiary hospitals, aided by the expansion of medical insurance coverage [1] Strategic Initiatives - 华领医药 is actively expanding its overseas business and accelerating its global layout [1] - The company continues to invest in research and development to support its expansion into international markets [1]
港股异动 | 华领医药-B(02552)再涨近6% 上半年首次实现盈利 全面自主商业化成效显著